Upshot Series Article 2



Safety is Top Priority in COVID-19 Vaccine #WeStandWithScience

Virus Covid-19

Sanofi and GSK Initiate Phase 1/2 Clinical Trial of COVID-19 Vaccine

small-molecule protein degraders

Driven by the Science: Small-Molecule Protein Degraders

Sanofi scientists are using protein degrader technology to design and develop drugs that could destroy key proteins in different types of cancer


The Fight against COVID-19

As the pandemic continues, Sanofi is at the forefront of vaccine development, while carrying on the daily business of making and delivering medicines for patients

woman writing on a transparent wall

Supporting People with Cancer during COVID-19

Despite the challenges caused by COVID-19, Sanofi continues to support the patient communities it serves—including the cancer community


The Last Mile: Innovative Breakthrough in Sleeping Sickness Treatment

Sanofi and DNDi are co-developing a second innovative treatment to strengthen their support for the sustainable elimination of sleeping sickness

Join Us!

You will join a diverse mix of people, who genuinely believe in our mission to help people around the world live healthier lives

  • Camera
    Press releases
    2020-09-21MMMM DD YYYY
    Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

How Multiple Sclerosis Affects the Brain

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies